SJ-172550

Research use only, not for human use.

The first small molecule MDMX inhibitor that reversibly binds the p53-binding pocket of MDMX.

The first small molecule MDMX inhibitor that reversibly binds the p53-binding pocket of MDMX, disrupts MDMX-p53 interaction with EC50 of 2.3 uM.

The p53 pathway is disrupted in virtually every human tumor. SJ-172550 binds the p53-binding pocket of MDMX, thereby displacing p53. SJ-172550 binds reversibly to MDMX and effectively kills retinoblastoma cells in which the expression of MDMX is amplified. The effect of SJ-172550 is additive when combined with an MDM2 inhibitor nutlin-3a. SJ-172550 acts through a complicated mechanism in which the compound forms a covalent but reversible complex with MDMX and locks MDMX into a conformation that is unable to bind p53. The relative stability of this complex is influenced by many factors including the reducing potential of the media, the presence of aggregates.

——

SJ172550 | SJ 172550

Apoptosis

MDM2-p53

MDM2-p53

Cancer

——

431979-47-4

428.8655

C22H21ClN2O5

>98% (HPLC)

10 mM in DMSO

ClC1=CC(/C=C2C(N(C3=CC=CC=C3)N=C\2C)=O)=CC(OCC)=C1OCC(OC)=O

Acetic acid, 2-[2-chloro-4-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)methyl]-6-ethoxyphenoxy]-, methyl ester

(-20℃)

With Ice Pack

≥ 2 years